Episode 38
At Last, COVID Treatments
Covid threatens those whose immune systems can’t make enough neutralizing antibodies to fight off the viral invaders. But what if scientists could make super-potent antibodies in the lab and infuse them into newly infected patients? That’s exactly what the first FDA-authorized coronavirus antibody treatment has achieved. Its maker, Eli Lilly, has generated clinical evidence that their therapy can significantly reduce COVID hospitalization rates when taken early.
November 30, 202031m 40s
Audio is streamed directly from the publisher (chtbl.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Covid threatens those whose immune systems can’t make enough neutralizing antibodies to fight off the viral invaders. But what if scientists could make super-potent antibodies in the lab and infuse them into newly infected patients? That’s exactly what the first FDA-authorized coronavirus antibody treatment has achieved. Its maker, Eli Lilly, has generated clinical evidence that their therapy can significantly reduce COVID hospitalization rates when taken early.
Topics
antibodypandemiccovidantibody therapyantibodieseuabiotechcovid19covid treatmentcorona virustherapyfda